Avidity Biosciences provided an update on the partial clinical hold related to its AOC 1001 product candidate, stating that the FDA has eased the hold, allowing the company to double the number of participants receiving 4 mg/kg of AOC 1001 in the MARINA-OLE study and enroll new participants at the 2 mg/kg dosage level.